WO2006038327A1 - グロビン蛋白分解物を含有する酵母発酵飲料 - Google Patents
グロビン蛋白分解物を含有する酵母発酵飲料 Download PDFInfo
- Publication number
- WO2006038327A1 WO2006038327A1 PCT/JP2005/005531 JP2005005531W WO2006038327A1 WO 2006038327 A1 WO2006038327 A1 WO 2006038327A1 JP 2005005531 W JP2005005531 W JP 2005005531W WO 2006038327 A1 WO2006038327 A1 WO 2006038327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beverage
- beer
- globin proteolysate
- yeast fermented
- fermented beverage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C5/00—Other raw materials for the preparation of beer
- C12C5/02—Additives for beer
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/84—Flavour masking or reducing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C5/00—Other raw materials for the preparation of beer
- C12C5/02—Additives for beer
- C12C5/026—Beer flavouring preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
Definitions
- the present invention relates to a beverage containing a globin proteolysate. More specifically, the present invention relates to a globin proteolysate-containing yeast fermented beverage that has a neutral fat increase-inhibiting effect and has reduced taste and odor peculiar to globin proteolysate.
- compositions obtained by decomposing globin proteins have an excellent effect of suppressing an increase in blood TG concentration and are safe. It was found to be excellent in performance.
- the active body is a mixture of oligopeptides having an average amino acid chain length of 3-5 typified by WYP (Val-Val-Tyr-Pro) and VTL (VaKThr-Leu). The effects of this degradation composition have also been confirmed in clinical trials (J.
- the globin proteolysate has a peculiar taste such as eda and bitterness, and a peculiar fragrance, and is difficult to use as a food material. Often to improve the flavor Sweeteners and fragrances are used. Flavor improvement by this means is available in recent years, such as Napledrink (registered trademark, Emji Pharma Co., Ltd.), Renefa (registered trademark, Yakult Co., Ltd.), Tacty TG (registered trademark, Rohto Pharmaceutical Co., Ltd.), T (Registered trademark, Morinaga & Co., Ltd.) has been tried in beverages using globin proteolysate. However, the flavor improvement is not sufficient to withstand long-term consumption. In preventing arteriosclerosis, it is necessary to suppress an increase in blood TG concentration over a long period of time. Therefore, it was necessary to improve the flavor to the extent that it could withstand long-term intake.
- Patent Document 1 JP-A-9-255698
- Non-Patent Document 1 J. Nut., 128, 56-60, 1998
- Non-Patent Document 2 Japan Nutrition's Journal of Food Science, 52, 71-77, 1999
- Non-Patent Document 3 Health 'Nutrition Food Research, 5, 131-144, 2002
- Non-Patent Document 4 Life Sci., 58, 1745-1755, 1996
- Non-Patent Document 5 Japan. J. Pharmacol., 58 (suppl. I), 80P, 1992
- the object of the present invention is to improve the unique taste and odor (fragrance) of globin proteolysate and to improve the Z content in beverages containing globin proteolysate having excellent neutral fat elevation inhibitory action. Or to provide a beverage containing a globin proteolysate that is easy to take for a long time.
- the flavor of yeast fermentation-derived components is effective in concealing the taste and smell of globin proteolysate.
- carbonated beverages such as beer, sparkling liquor, and beer-taste soft drinks
- the foaming effect also added the effect of promoting the spread of the flavor of yeast-derived components, and the concealment effect was increased. That is, it was confirmed that by using a yeast fermented beverage as a base beverage, a beverage having a taste and smell that can be drunk without resistance for a long time can be produced.
- the present invention is a yeast fermented beverage containing a globin proteolysate, which significantly improves the flavor derived from the globin proteolysate.
- the yeast fermented beverage is a general term for beverages manufactured through a fermentation process.
- yeast-fermented beverages are usually produced through the process of adding yeast to a sugar solution obtained from malt and grains such as barley, rice, corn, and sugars, and fermenting them. Instead, plant proteins or their degradation products may be used.
- yeast fermented beverages include those that have been given a flavor similar to that derived from fermentation with a flavoring agent that does not necessarily have to have undergone a fermentation process. Accordingly, yeast fermented beverages include, for example, sake, synthetic sake, shochu, mirin, beer, sparkling wine, beer-taste soft drinks, fruit liquors, whiskeys, spirits, liqueurs and miscellaneous sake.
- the yeast fermented beverage is preferably a beer-taste beverage.
- the beer-taste beverage refers to a beverage having a beer-like flavor, for example, a fermented incense or a hop incense, and preferably includes beer, sparkling liquor, beer-taste soft drink, miscellaneous sake, and liqueurs. This is a soda.
- the beer as used in the present invention is a beer-taste beverage having an alcohol content of 1% by volume or more, preferably 3-7% by volume, and a malt use rate of 67% by weight or more during production.
- Happoshu is a beer-taste beverage with an alcohol content of 1% by volume or more, preferably 3-7% by volume, and a malt use ratio of less than 67% by weight. What has foamability.
- beer taste soft drinks referred to in the present invention is that of low-alcohol beer of less than alcohol content of 1 capacity 0/0.
- beer-taste beverages that are classified as liquor are beverages with an alcohol content of 1% by volume or more, and beer-taste beverages with an alcohol content of less than 1% by volume are not classified as liquors. So called.
- the alcohol content is between 0.1% and less than 1% by volume. Beer-taste soft drinks are also called non-alcoholic beer or alcohol-free beer.
- Beer-taste soft drinks are, for example, (1) dilution method, (2) method of removing alcohol from beer (reverse osmosis membrane method or distillation method), (3) method of using special yeasts or microorganisms, ( 4) A method for stopping fermentation in the middle of fermentation, and (5) a method for producing by blending an additive such as a fragrance with a sugar solution that does not pass through the fermentation step are known. When used for drinks, it may be prepared in a different way.
- liqueur having a beer taste and miscellaneous sake having a beer taste can also be suitably used.
- the yeast used in the production of the yeast fermented beverage according to the present invention can be freely selected in consideration of the type of product, target flavor, fermentation conditions, and the like.
- NCYC-229 purchasedd from NATIONAL COLLECTION OF YEAST CULTURES
- NCYC-401 purchasedd from NATIONAL COLLECTION OF YEAST CULTURES
- Weihenstephan- 184 (purchased from NATIONAL COLLECTION OF YEAST CULTURES)
- a colorant, an antioxidant, a sour agent, a fragrance and the like are added to the mash obtained by stopping the fermentation according to a conventional method, if necessary. If necessary, the alcohol concentration and flavor of the beverage can be adjusted by diluting with a reverse osmosis membrane method or water.
- the globin protein degradation product may be blended or mixed with the yeast fermented beverage thus obtained.
- Yeast-fermented beverages can be filled into containers such as bottles and cans after undergoing a sterilization process as necessary.
- the globin proteolysate has a higher concentration than the conventional beverage. On the other hand, it became clear that the effect of improving the flavor was exhibited.
- the concentration of the globin proteolysate in the present invention is preferably 0.1 to 1.5 gZlOOml, more preferably 0.1 to 1. OgZ 100 ml, and still more preferably 0.1 to 0.7 g / 100 ml.
- the pH in the beverage according to the present invention is preferably in the range 3.0-4.5, more preferably 3.5-4.5, even more preferably 3.7-7.0. If the pH of the beverage after fermentation falls outside this range, the pH may be adjusted by adding a pH adjuster as appropriate.
- the pH adjusting agent includes, but is not limited to, lactic acid, phosphoric acid, citrate and the like.
- the globin proteolysate as used in the present invention is a peptide mixture mainly composed of an oligopeptide having an average amino acid chain length of 3-5, which is obtained by hydrolyzing the globin protein constituting hemoglobin or myoglobin.
- Hemoglobin and myoglobin are preferably derived from ushi, pig, hidge, human, horse and the like, and particularly preferably derived from ushi or pig blood.
- Hydrolysis is preferably carried out using one or more proteases selected from the group forces consisting of acidic proteases, neutral proteases and alkaline proteases. In particular, it is preferable to use acidic proteases, especially those derived from Aspergillus niger.
- the globin protein-containing material is first dispersed in water so as to be 5 to 30% by weight as a solid content, and the dispersion is optimized with protease by using acid or alkali. Adjust to pH and add 0.1-5 units of protease at a time or sequentially to 0.1 mg of protein in the dispersion at 20-70 ° C. The reaction is carried out by reacting the protease for a period of time, preferably 16-30 hours.
- 1 unit of protease refers to the increase in non-protein forin test solution colorant equivalent to 1 ⁇ g of tyrosin per minute at 30 ° C at the enzyme's optimum pH, using milk casein as a substrate.
- the molecular weight distribution of the oligopeptide in the globin proteolysate is 100-1500.
- the molecular weight distribution measurement can be performed by any commonly used method. For example, it is preferable to measure using a gel filtration method.
- the average amino acid chain length of the oligopeptide contained in the hydrolysis product can be measured by a known method such as a combination of chromatography and mass spectrometry.
- JP-A-9 255698 as a main active ingredient of a globin proteolysate, SEQ ID NO: 1 peptide of VVYP (VaV VaKTyr-Pro) and peptide VTL (VaKThr-Leu) are isolated, These peptides have been reported to have potent inhibitory activity against elevated serum triglyceride levels.
- the globin proteolysate of the present invention contains at least 0.1% by weight of WYP or VTL.
- the globin proteolysate is, in its broadest sense, an oligopeptide VVYP and / or VTL separated from the globin proteolysate according to, for example, the description of JP-A-9-255698. Is also included.
- the globin proteolysate can be purified by ion exchange resin, ultrafiltration, reverse phase column chromatography, etc., if necessary. It has been clarified that the removal of free amino acids by ultrafiltration after ion exchange resin treatment increases serum TG elevation inhibitory activity (JP-A-9-255698).
- a globin proteolysate suitable for use in the present invention is commercially available, and can be purchased from, for example, MG Pharma Corporation.
- the globin proteolysate is a oligopeptide mixture having an average amino acid residue 3- 5, VVYP comprises from about 0.6 weight 0/0 degree to, and the molecular weight distribution of 100 - 1500.
- the present invention also relates to a method for reducing the taste and smell peculiar to globin proteolysate in beverages containing globin proteolysate.
- the method includes using a yeast-fermented beverage as the base beverage of the beverage containing the globin proteolysate.
- the globin proteolysate-containing beverage in the method preferably also has one or more of the characteristics described above with respect to the base beverage, degradation product, degradation product concentration, pH, and pH adjuster.
- the present invention provides an effect of suppressing an increase in serum triglyceride concentration or an increase in neutral fat. It also relates to a yeast fermented beverage containing a globin proteolysate, which is labeled as having an effect.
- the display location may be a container or instructions attached to it. Beverage containers include, but are not limited to, barrels, bottles, cans and plastic bottles. Also, the display method is not limited to force including printing, engraving, sealing, and the like.
- the effect of suppressing the increase in triglyceride refers to the effect of reducing the triglyceride concentration in the blood of an animal.
- the neutral fat is preferably triglyceride (TG).
- the serum TG fat inhibitory effect can be evaluated as described in Example 5 described later, but it may be according to the method described in JP-A-9-255698. It can be evaluated, for example, by administering a test sample together with a diet to a specimen animal and measuring the TG concentration of blood collected from the animal after a certain time. The TG concentration is measured, for example, by using an automatic analyzer (Hitachi 7070, Hitachi, Ltd.) or triglyceride G test KOKO (Wako Pure Chemical Industries).
- the amount of globin proteolysate required to exhibit a neutral fat elevation inhibitory activity is about 1 mg of globin proteolysate per adult per day. Therefore, it is desirable that the beverage of the present invention contains 1 mg or more of globin proteolysate in the intake amount per time. However, when the beverage of the present invention is taken in several portions, the content can be less than 1 mg.
- a globin proteolysate-containing yeast fermented beverage having an excellent flavor and an effect of suppressing the increase in neutral fat.
- the beverage of the present invention is suitable for long-term consumption due to its excellent flavor.
- the beverage is a beer-taste beverage.
- Beer-taste beverages including beer, happoshu, and beer-taste soft drinks, have a strong preference. Therefore, if a globin proteolysate is added to these beverages without losing their flavor, it is expected that consumption can be continued more easily than conventional globin proteolysate-containing beverages.
- yeast fermented beverages such as beer-taste beverages are generally high in fats and oils! There are many. Therefore, if these beverages are given a neutral fat elevation-inhibiting effect, it is expected that hyperlipidemia can be prevented and / or treated at an appropriate timing by taking them.
- Fig. 1 is a graph showing the transition of serum triglyceride concentration in all subjects who took the globin proteolysate (GD) -containing beverage or control beverage of the present invention together with a fat diet. ⁇ shows the results when ingesting GD-containing beverages, and ⁇ shows the results when ingesting control beverages.
- GD globin proteolysate
- FIG. 2 is a graph showing the transition of serum triglyceride concentration in a group of healthy subjects who took the globin proteolysate (GD) -containing beverage or control beverage of the present invention together with a fat diet. ⁇ shows the results when ingesting GD-containing beverages, and ⁇ shows the results when ingesting control beverages.
- GD globin proteolysate
- FIG. 3 is a graph showing the transition of serum triglyceride concentration in a hyper-TG group in which the globin proteolysate (GD) -containing beverage or control beverage of the present invention was ingested with a fat diet. ⁇ indicates the results when GD-containing beverages are ingested, and ⁇ indicates the results when the control beverages are ingested.
- GD globin proteolysate
- the unit (%) used in relation to the content of globin degradation product shall have the same meaning as g ZlOOml.
- the effect of concealing the flavor derived from the globin proteolysate was evaluated using various base beverages. In consideration of the fact that it was consumed during the meal, the base beverages tested were also selected for their unsweetened drinking power.
- the evaluation items were three items: aroma (presence / absence of odor characteristic of globin proteolysate), taste (presence / absence of gummy taste), and difference in flavor from the beverage without added globin proteolysate.
- aroma presence / absence of odor characteristic of globin proteolysate
- taste presence / absence of gummy taste
- difference in flavor from the beverage without added globin proteolysate was conducted by six trained examiners.
- the flavor was evaluated in the range of 1 point (very difficult to drink) and 5 points (very easy to drink).
- the difference in flavor from beverages without globin proteolysate was evaluated in the range of 1 point (very different) to 15 points (no difference).
- 3 points were set as standard evaluations (acceptable), and evaluations were made in increments of 0.5 points.
- the scores obtained from each tester are averaged for each base beverage, and the results are shown in Table 1. An average score of 3 points or more is indicated as ⁇ , 2 points or more and less than 3 points as ⁇ , and less than 2 points as X.
- beer, sparkling liquor, beer-taste soft drinks, whiskeys and brandies have a high scent and taste concealing effect, and there is also a difference in flavor from additive-free beverages. It was an unacceptable force.
- beer-taste beverages such as beer, happoshu and beer-taste soft drinks have been highly evaluated for their concealing effect on aroma and taste, and have been found to be easy to drink.
- red wine and barley shochu also showed a slight improvement in flavor that does not show a significant difference in flavor from the globin proteolysate-free beverage.
- beer, happoshu and beer-taste soft drinks that are widely spread as food drinks can be suitably used as beverages that conceal or reduce the flavor derived from globin proteolysate.
- beverages having effervescent properties and flavors derived from yeast fermentation preferably beer-taste beverages, are considered suitable for reducing the flavor derived from globin proteolysate.
- Example 1 Using beer and beer-taste soft drinks that had a flavor concealing or reducing effect in Example 1 as base beverages, the amount of added globin proteolysate was varied to examine the influence on the flavor concealing or reducing effect.
- the globin proteolysate Since the globin proteolysate has a high amino acid content, it exhibits pH buffering ability when added to beverages. For this reason, the pH of the beverage after preparation varies depending on the amount of globin proteolysate added. In order to eliminate the effects of such pH differences, in this study, evaluation was carried out after adjusting the pH of all test beverages to 4.0 by adding citrate. The sensory test was conducted by six trained examiners. Evaluation items and evaluation methods were the same as in Example 1.
- the technique of the present invention is effective for the globin proteolysate concentration at which the influence of the flavor of the globin proteolysate began to appear in the control, that is, 0.1% or more. It became power. Further, it is also clear that the upper limit concentration of the globin proteolysate obtained by the present invention with a scent reducing effect is 1.5%, and the upper limit concentration with which the scent and taste reducing effect is obtained is 1.0%. It became power.
- Tsu to the beverage having various P H, Te, fragrance were evaluated for palatability of as taste, and beverages.
- the evaluation method of aroma and taste was in accordance with Example 1. In terms of ease of drinking as a beverage, there were 5 levels, 1 point (very difficult to drink) and 5 points (very easy to drink! /). Three points were standard evaluations (acceptable), and evaluations were made in increments of 0.5 points. The average score is indicated as ⁇ for 3 points or more, ⁇ for 2 or more and less than 3 points, and X for less than 2 points.
- the pH of the beverage is preferably 3.0-4 regardless of the type of pH adjuster. .5, more preferably 3.5-4.5, and even more preferably 3.7-7.
- Example 4 Example of production of beer-taste beverage containing globin proteolysate
- a beer-taste soft drink was selected as the base drink, and the drink of the present invention was produced on a pilot scale.
- Hyperlipidemia Guidelines Japanese Arteriosclerosis Society Hyperlipidemia Guideline Committee: Hyperlipidemia Guidelines I Diagnosis criteria, treatment application criteria, treatment target values for adult hyperlipidemia. Arteriosclerosis, 25, 1 According to -34, 1997), a condition with a serum TG value of 150 mg / dl or higher is called hyperTGemia. Also, Tadao Yasugi's “Chemistry of Lipids” (Asakura Shoten, pp. 126-133, 1990) called serum TG levels 111-149 mgZdl as borderline hyperTGemia from the perspective of risk of arteriosclerosis. It is out. Therefore, in this study, those with a fasting serum TG of 1 lOmgZdl or less were considered healthy, and those with 11 lmgZdl or more were treated with hyperTG.
- Serum TG level is relatively high (TGl lmgmgdl or higher) in regular health check-up (within 3 months) Recruitment of adult males and females and treatment with hyperlipidemia, etc. Selected for name. This included 12 hyperTG patients and 9 healthy individuals.
- the food used for the test was a drink containing globin proteolysate (GD) and a fat-eating power.
- GD globin proteolysate
- Beverages containing GD are based on beer-taste beverages, and 1 GD per bottle (350ml). Including g (about 0.29 g Zl00 ml), pH was 3.8. The calorie per bottle was about 55 kcal.
- the beverage used as a control was the same as the beverage containing GD except that it did not contain GD, and the appearance and shape of the beverage containing GD could not be distinguished.
- GD EMS Pharma Co., Ltd.
- GD is an oligopeptide mixture of average amino acid residues 3-5, molecular weight distribution 100-1500, protein content 92% by weight (free amino acid 10% by weight), carbohydrate 2 It was 3% by weight, ash content 2.9% by weight, and water content 2.8% by weight.
- the fat meal is 200 g of commercially available corn cream potage soup (corn cream potage, Daikoya Dairy Co., Ltd.), 19 g of butter (butter (no salt), Snow Brand Milk Products Co., Ltd.) and lard (lard, snow brand) Dairy Co., Ltd.) 15g was added.
- the test was performed by the cross test method. Allow subject to ingest 1 bottle of GD drink and fat diet (containing 40 g of fat) at the same time, provide a recovery period of 1 week, and then ingest 1 bottle of control drink and fat diet, or vice versa. Ingested in order. The subjects were randomly assigned in line V, and the subjects were not informed of the beverage contents! /, Blinded.
- the subjects were fasted from 9:00 pm the night before the test, and the test started at 9:00 the following morning. During the test, they were fasted and only a small amount of water was allowed. The amount of exercise of the subjects was limited, and the subjects were sitting at rest or light work. Blood was collected (approximately 5 mL) from the radial vein before intake of the test meal or control meal and 1, 2, 3, 4, 5, 6 and 7 hours after intake.
- Blood was collected in a separating agent-added tube, allowed to stand at 5 ° C for about 30 minutes, and then centrifuged at 1, OOOg for 15 minutes to obtain serum.
- Serum TG was measured by an enzymatic method using an automatic analyzer (Hitachi 7070, Hitachi, Ltd.). At the same time, chylomicron, VLDL (very low density lipoprotein) Quality). In chylomicron, dietary fat is absorbed in the small intestine and appears in the blood. VLDL is an ultra-low density lipoprotein and is known to be easily metabolized to low density lipoprotein (LDL), which is known as a lipoprotein that causes arteriosclerosis. The measurement of these lipoprotein fractions was performed using the serum lipoprotein fraction measurement kit “BLF 'Eiken' 11” (registered trademark, Eiken Igaku) using the dextran sulfate turbidimetric method.
- BPF 'Eiken' 11 registered trademark, Eiken Igaku
- RLP cholesterol proliferative lipoprotein
- RLP-cholesterol is thought to reflect chylomicron remnant concentrations.
- the chylomicron remnant is an intermediate metabolite in which chylomicron is partially hydrolyzed by lipase, and is known to be an arteriosclerosis-induced lipoprotein.
- RLP Cholesterol is thought to reflect chylomicron remnant concentrations.
- the chylomicron remnant is an intermediate metabolite in which chylomicron is partially hydrolyzed by lipase, and is known to be an arteriosclerosis-induced lipoprotein.
- AUC area under the blood concentration curve
- the measured value was displayed as an average value standard error.
- the inhibitory effect of GD beverage on the increase in serum lipid concentration after intake of the test meal was evaluated using measured values and AUC at each hour. These results were analyzed by a one-way analysis of variance with the control group (L lump method).
- the significance level was defined as a significance level of a risk rate of less than 5%.
- Serum TG was measured over time by ingesting a GD-containing beverage or a control beverage together with a fat diet to subjects in a healthy group and a hyper-TG group. The results are shown in Figure 1-13. Serum TG concentration (sTG) is expressed in mgZdl. Black circles ( ⁇ ) indicate the results when GD-containing beverages are ingested, and white circles ( ⁇ ) indicate the results when the control beverages are ingested.
- the beverage of the present invention has a favorable effect for the prevention and treatment of hyperlipidemia in addition to the effect of suppressing TG elevation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Non-Alcoholic Beverages (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002582318A CA2582318A1 (en) | 2004-09-30 | 2005-03-25 | Globin digest containing, yeast-fermented beverages |
US11/664,159 US20080063781A1 (en) | 2004-09-30 | 2005-03-25 | Globin Digest Containing, Yeast-Fermented Beverages |
JP2006539146A JP4769193B2 (ja) | 2004-09-30 | 2005-03-25 | グロビン蛋白分解物を含有する酵母発酵飲料 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-287936 | 2004-09-30 | ||
JP2004287936 | 2004-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038327A1 true WO2006038327A1 (ja) | 2006-04-13 |
Family
ID=36142415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005531 WO2006038327A1 (ja) | 2004-09-30 | 2005-03-25 | グロビン蛋白分解物を含有する酵母発酵飲料 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080063781A1 (ja) |
JP (1) | JP4769193B2 (ja) |
CA (1) | CA2582318A1 (ja) |
WO (1) | WO2006038327A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008105959A (ja) * | 2006-10-23 | 2008-05-08 | Mg Pharma Kk | 肝障害改善組成物 |
JP2012239460A (ja) * | 2011-05-24 | 2012-12-10 | Asahi Breweries Ltd | 低アルコール発酵麦芽飲料の製造方法 |
CN102943015A (zh) * | 2012-11-29 | 2013-02-27 | 刘淑银 | 一种保健啤酒 |
JP2013116911A (ja) * | 2007-08-07 | 2013-06-13 | Mg Pharma Kk | 血圧降下剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014103011A1 (ja) | 2012-12-28 | 2014-07-03 | サントリーホールディングス株式会社 | 味の締まりが付与された、ノンアルコールのビールテイスト飲料 |
AR092102A1 (es) * | 2012-08-14 | 2015-03-25 | Dsm Ip Assets Bv | Hidrolizado de proteinas |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255698A (ja) * | 1996-03-22 | 1997-09-30 | Hankyu Kyoei Bussan Inc | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 |
JP2002281948A (ja) * | 2001-03-27 | 2002-10-02 | Kanegafuchi Chem Ind Co Ltd | 風味が改善された飲料 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3407167B2 (ja) * | 1995-08-21 | 2003-05-19 | 理研ヘルス株式会社 | コウライニンジンを含有する麦芽発酵飲料 |
JP2001252064A (ja) * | 2000-03-13 | 2001-09-18 | Matsutani Chem Ind Ltd | 食物繊維を含有するビール又は発泡酒 |
JP2002291460A (ja) * | 2001-03-30 | 2002-10-08 | Kyodo Shoji:Kk | 醸造酒の製造方法及び醸造酒 |
JP4210514B2 (ja) * | 2001-12-27 | 2009-01-21 | アサヒビール株式会社 | 高ギャバ含有アルコール飲料の製造方法 |
US20030157218A1 (en) * | 2002-02-20 | 2003-08-21 | Donhowe Erik Thurman | Product and process of making a protein, vitamin, mineral and antioxidant fortified sport beer |
-
2005
- 2005-03-25 WO PCT/JP2005/005531 patent/WO2006038327A1/ja active Application Filing
- 2005-03-25 JP JP2006539146A patent/JP4769193B2/ja not_active Expired - Fee Related
- 2005-03-25 CA CA002582318A patent/CA2582318A1/en not_active Abandoned
- 2005-03-25 US US11/664,159 patent/US20080063781A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255698A (ja) * | 1996-03-22 | 1997-09-30 | Hankyu Kyoei Bussan Inc | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 |
JP2002281948A (ja) * | 2001-03-27 | 2002-10-02 | Kanegafuchi Chem Ind Co Ltd | 風味が改善された飲料 |
Non-Patent Citations (1)
Title |
---|
ORMROD I.H.L.; EALOR E.F.; SHARPE F.R.: "The release of yeast proteolytic enzymes into beer", J.INST.BREW., vol. 97, no. 6, November 1991 (1991-11-01), INSTITUTE OF BREWING. LONDON, GB, pages 441 - 443, XP002990332 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008105959A (ja) * | 2006-10-23 | 2008-05-08 | Mg Pharma Kk | 肝障害改善組成物 |
JP2013116911A (ja) * | 2007-08-07 | 2013-06-13 | Mg Pharma Kk | 血圧降下剤 |
JP2013144696A (ja) * | 2007-08-07 | 2013-07-25 | Mg Pharma Kk | 血圧降下剤 |
JP2016026194A (ja) * | 2007-08-07 | 2016-02-12 | エムジーファーマ株式会社 | 血圧降下剤 |
JP2012239460A (ja) * | 2011-05-24 | 2012-12-10 | Asahi Breweries Ltd | 低アルコール発酵麦芽飲料の製造方法 |
CN102943015A (zh) * | 2012-11-29 | 2013-02-27 | 刘淑银 | 一种保健啤酒 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006038327A1 (ja) | 2008-05-15 |
CA2582318A1 (en) | 2006-04-13 |
JP4769193B2 (ja) | 2011-09-07 |
US20080063781A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6577562B2 (ja) | コラーゲンペプチド含有飲料の臭気抑制技術 | |
RU2217009C2 (ru) | Добавка к напитку и способ производства напитка | |
KR101350663B1 (ko) | 신맛이 감소·완화된 미발효된 맥주 풍미 맥아 음료 및 그의 제조 방법 | |
JP4769193B2 (ja) | グロビン蛋白分解物を含有する酵母発酵飲料 | |
RU2580369C2 (ru) | Безалкогольный напиток со вкусом пива, имеющий улучшенное послевкусие | |
RU2564070C1 (ru) | Безалкогольный напиток со вкусом пива с высоким соотношением моносахаридов и дисахаридов | |
TWI649035B (zh) | 無酒精之啤酒風味飲料 | |
JP6251760B2 (ja) | 容器詰発泡飲料 | |
US20120177799A1 (en) | Vinegar-based soft drink | |
JP2011239739A (ja) | 酸味が低減・緩和された未発酵のビール風味麦芽飲料およびその製造方法 | |
JP6957229B2 (ja) | ノンアルコールのビールテイスト飲料 | |
JPS62143678A (ja) | 深酔い防止アルコ−ル飲料の製造法 | |
TW202031886A (zh) | 啤酒風味飲料 | |
TW201904442A (zh) | 碳酸飲料、容器裝碳酸飲料及碳酸飲料之酸酪乳風味增強方法 | |
RU2238310C1 (ru) | Слабоалкогольный напиток "абсентер энерджи" | |
WO2016147907A1 (ja) | ノンアルコールのビールテイスト飲料 | |
JP6960257B2 (ja) | ノンアルコールのビールテイスト飲料 | |
TWI417056B (zh) | Sour taste reduced ‧ Efforts of unfermented beer flavored malt beverages and their manufacturing methods | |
CN1699537A (zh) | 一种奶啤饮料及其制备方法 | |
CN1699531A (zh) | 一种乳清啤饮料及其制备方法 | |
JP4338233B2 (ja) | 食欲増進飲食物 | |
JP2003102451A (ja) | 黒麹もろみ酢からなる健康飲料 | |
WO2020116383A1 (ja) | 飲料及び飲料の製造方法 | |
JP2024077835A (ja) | 柑橘系飲料及びその製造方法 | |
SU1409196A1 (ru) | Способ производства молочно-фруктового концентрата "глори " дл газированных напитков |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2582318 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006539146 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11664159 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05727142 Country of ref document: EP Kind code of ref document: A1 |
|
WWP | Wipo information: published in national office |
Ref document number: 11664159 Country of ref document: US |